Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McMaster University

$28,870.00

Materials for drug and cell delivery in ophthalmic applications

EF 2010-11

Résumé
Vision loss in Canada due to such diseases as age related macular degeneration, glaucoma and diabetic retinopathy , is increasing at a dramatic rate with the aging of the population. Estimates suggest that the current 2.1 million Canadians with AMD will triple over the next 25 years. In addition to the obvious consequences, vision loss also has a significant effect on patient quality of life. People with vision impairment, compared to the visually competent population of the same age, are admitted to nursing homes three years earlier, suffer from depression at a rate that is three times higher, fall twice as often, suffer hip fractures at a rate that is four times higher, and are twice as likely to die prematurely. While the real costs of these diseases are unknown, it has been estimated that total direct cost to governments in Canada for glaucoma alone in 2001 was CDN$300 million. The effectiveness of novel therapeutics under development for treating these diseases, particularly diseases of the back of the eye, is limited by the inaccessibility of this tissue. Furthermore, reversal of these diseases will ultimately require cell replacement through delivery of cellular components. The Sheardown research program is aimed at developing novel biomaterials for treatment of vision disorders by replacing diseased or damaged tissue with appropriate cellular components coupled with a biomaterial scaffold or by augmenting existing treatment methods by controlling and prolonging delivery of therapeutic agents. The program encompasses a broad range of ocular diseases and vision disorders including diseases of front and back of the eye as well as refractive problems. By exploiting the biological characteristics of the specific ocular system, we will, through this program, develop a suite of materials, comprised of both synthetic and natural polymers with various properties, for treating vision disorders.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
197331-2008
Name nom
Sheardown, Heather
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2008
Award amount
28870
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
4
Committee name en
Chem. & Metallurgical Eng.
Committee name fr
Génies chimique et métal.
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
3
Nb partie
5
Application title
Materials for drug and cell delivery in ophthalmic applications
Keyword
NSERC
Application summary
Vision loss in Canada due to such diseases as age related macular degeneration, glaucoma and diabetic retinopathy , is increasing at a dramatic rate with the aging of the population. Estimates suggest that the current 2.1 million Canadians with AMD will triple over the next 25 years. In addition to the obvious consequences, vision loss also has a significant effect on patient quality of life. People with vision impairment, compared to the visually competent population of the same age, are admitted to nursing homes three years earlier, suffer from depression at a rate that is three times higher, fall twice as often, suffer hip fractures at a rate that is four times higher, and are twice as likely to die prematurely. While the real costs of these diseases are unknown, it has been estimated that total direct cost to governments in Canada for glaucoma alone in 2001 was CDN$300 million. The effectiveness of novel therapeutics under development for treating these diseases, particularly diseases of the back of the eye, is limited by the inaccessibility of this tissue. Furthermore, reversal of these diseases will ultimately require cell replacement through delivery of cellular components. The Sheardown research program is aimed at developing novel biomaterials for treatment of vision disorders by replacing diseased or damaged tissue with appropriate cellular components coupled with a biomaterial scaffold or by augmenting existing treatment methods by controlling and prolonging delivery of therapeutic agents. The program encompasses a broad range of ocular diseases and vision disorders including diseases of front and back of the eye as well as refractive problems. By exploiting the biological characteristics of the specific ocular system, we will, through this program, develop a suite of materials, comprised of both synthetic and natural polymers with various properties, for treating vision disorders.